Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases (Q38197368)

30 August 2017

1 reference

title

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases (English)

1 reference

30 August 2017

0 references

1

1 reference

PubMed ID

24646283

30 August 2017

language of work or name

1 reference

1 April 2014

1 reference

Biochemical Society Transactions

30 August 2017

1 reference

30 August 2017

42

1 reference

30 August 2017

2

1 reference

30 August 2017

593-599

1 reference

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.

30 August 2017

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Parkinson's disease, insulin resistance and novel agents of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Insulin and cognitive function in humans: experimental data and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Hyperinsulinemia and risk of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Neurodegenerative disorders associated with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Risk of dementia among persons with diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Increased risk of type 2 diabetes in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucose tolerance status and risk of dementia in the community: the Hisayama study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Insulin resistance impairs nigrostriatal dopamine function

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucose metabolism and insulin receptor signal transduction in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Insulin-like growth factor-I, cognition and brain aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Insulin and the insulin receptor in experimental models of learning and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Lixisenatide: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Exenatide and the treatment of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Exercise builds brain health: key roles of growth factor cascades and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Hope for AD with NGF gene-therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140016

21 January 2018

Identifiers

DOI

10.1042/BST20140016

1 reference

30 August 2017

1 reference

PubMed ID

24646283